Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromomethane SCHEMBL6308629 | 0.94 | MAPT (0.42) | PTPN1MAPTCES2CES1POLB | |
| SCHEMBL71405 | 0.88 | CYP2C9 (0.48) | PTPN1MAPTCES2CES1POLB | |
| SCHEMBL27396838 | 0.83 | PTPN1 (0.42) | PTPN1MAPTCES2CES1POLB | |
| SCHEMBL27465214 | 0.83 | PTPN1 (0.42) | PTPN1MAPTCES2CES1POLB | |
| SCHEMBL71754 | 0.83 | MAPT (0.42) | PTPN1MAPTCES2CES1POLB | |
| SCHEMBL4636478 | 0.81 | GAA (0.37) | MAPTPOLBKMT2ACYP2C9PKM | |
| SCHEMBL11279510 | 0.80 | CHRM3 (0.42) | PTPN1MAPTCES2CES1POLB | |
| SCHEMBL30230256 | 0.80 | CES1 (0.44) | PTPN1MAPTCES2CES1KMT2A | |
| SCHEMBL73485 | 0.79 | CHRM3 (0.41) | PTPN1MAPTCES2CES1POLB | |
| SCHEMBL8478567 | 0.78 | PTPN1 (0.42) | PTPN1MAPTCES2CES1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200431-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL PRODESFARMA AG (CH) | 2003-03-26 | — | — | EP | claimed |
| CN-118000207-A | Soluble composition and preparation method and application thereof | 江苏山川科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-116790411-A | Camel milk source Leng Yi raw bacteria strain for producing GABA and application | 新疆大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-116349693-A | Composition capable of enhancing lodging resistance and increasing yield of grain crops as well as preparation method and application thereof | 王伟中 | 2023-06-30 | — | — | CN | disclosed |
| CN-115968286-A | Heteroaryl compounds, their preparation and use | 益方生物科技(上海)股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-109844536-B | Predicting response to PD-1 axis inhibitors | 豪夫迈·罗氏有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-109563155-B | Antibodies, compositions and kits comprising the same, and methods of use thereof | 北京伟德杰生物科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-108883164-B | Antibodies to TIGIT | JN生物科学有限责任公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-109689087-B | Targeted mutant interferon-beta and uses thereof | 奥里尼斯生物科学私人有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115894606-A | RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| US-7232835-B2 | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-19 | — | — | US | disclosed |
| US-20060217432-A1 | 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | US | disclosed |
| US-20060106056-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-05-18 | — | — | US | disclosed |
| EP-1572648-A1 | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-14 | — | — | EP | disclosed |
| US-20050038252-A1 | New difurylglycolic acid esters processes for the preparation thereof as well as the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004052857-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-24 | — | — | WO | disclosed |
| US-6750226-B2 | FOR MANUFACTURE OF MEDICAMENT FOR USE IN THERAPY OF RESPIRATORY, URINARY OR GASTROINTESTINAL DISEASE | ALMIRALL-PRODESFARMA, S.A. (ES) | 2004-06-15 | — | — | US | disclosed |
| US-20030229227-A1 | New difurylglycolic acid esters, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-11 | — | — | US | disclosed |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | ALMIRALL, S.A. (ES) | 2003-03-20 | — | — | US | disclosed |
| US-5821256-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217432-A1 | 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | PTPN1 1192/4885MAPT 3672/4885CES2 1660/4885 |
| US-20030229227-A1 | New difurylglycolic acid esters, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions | GYS1, GUCY1B1, UGGT1 | PTPN1 1889/4885MAPT 4240/4885CES2 1608/4885 |
| US-20060106056-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | CHRM3, CHRM4, CHRM2 | PTPN1 908/4885MAPT 4395/4885CES2 2086/4885 |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | NR1H4, CHRM3, CHRM4 | PTPN1 2070/4885MAPT 4470/4885CES2 2352/4885 |
| US-20050038252-A1 | New difurylglycolic acid esters processes for the preparation thereof as well as the use thereof as pharmaceutical compositions | GYS1, GRHPR, GUCY1B1 | PTPN1 1746/4885MAPT 4164/4885CES2 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.